PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 4995-no persons are	required to respond to a collection of it	nformation unless it contains a valid OMB control number
701.6	. Coquiros os con	Complete if Known
Substitute for form 1449A/PTO	Application Number	09/976,249
MAP 2 0 2003	Filing Date	October 15, 2001
STATEMENT BY APPLICANT	First Named Inventor	Giorgio ATTARDO
\ <b>Z</b>	Group Art Unit	1654
(use as many sheets as vecessary)	Examiner Name	Michael V. Meller
Sheet 1 of 2	Attorney Docket Number	PHARMA-123

				U.S. PATENT DOCUM	ENIS	
Examiner Cite U.S. Patent Document Kind Code <sup>2</sup>		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
Initials *	No.1	Number	(if known)	Applicant of Cited Document	MM-DD-YYYY	Figures Appear
				1		
	<del> </del>					DECEIVE
						200
	<b> </b>					
					-	TECH CENTER 160
		<del> </del>				TECH CENTER TO
	-					
				3		
	+					
	-					
					<u> </u>	<u> </u>

				FORE	GN PATENT DOCUME	ENTS	S. Lines T	
Examiner Initials*	Cite No.1	For Office <sup>3</sup>		ment ind Code <sup>5</sup> if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Тв
AAN/AA	1	+	EP0037713	A2	Belleau et al	10/18/1989		
MM		+	WO 00/57861	A2	Gourdeau et al	10/05/2000		
1/	3	+	WO 96/07413	A1	Chu et al	03/14/1996 .		
<del></del>								
				<del> </del>				
	ļ							<u> </u>
	<del> </del>							
	+		1		4		<u> </u>	

1					
		. 7			
		<del>/                                    </del>	D-40		
Examiner	1 //1./1 //	11.	Date	1/2/2/102	
	10/1/1,0/		Considered	(///////	
Signature	1 1/0 17 0			i the state of not	in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code Onique citation designation number. See attached kinds of 0.5. Patent Documents. Effect Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. For Japanese patent documents, the indication of the document under WIPO Standard ST. 16 if possible. Applicant is patent document. Standard ST. 16 if possible of Applicant is to place a check mark hee if English language Translation is attached.

PTO/SB/08A (08-00)

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no page 1995, page 1995, no page 1995

Substitute for form 1449A/PTO	Complete if Known RECEIVED				
	Application Number	09/976,249			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	October 15, 2001 MAR 2 1 2003			
	First Named Inventor	Giorgio ATTARDO			
	Group Art Unit	1654			
(use as many sheets as necessary)	Examiner Name	Michael V. Meller TECH CENTER 160 0/2900			
Sheet 2 of 2	Attorney Docket Number	PHARMA-123			

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/o country where published.		
4	K.L. Grove et al, "Beta-L-(-)-Dioxolane Cytidine As A Potent Compound For The Treatment Of Cancer", Nucleosides & Nucleotides, Vol. 16, No. 7-9, 1997, pp. 1229-33, XP000971189	
5	S.A. Kadhim et al, "Potent Antitumor Activity Of A Novel Nucleoside Analogue", Cancer Research, Vol. 57, November 1, 1997, pp. 4803-4810, XP000971188	
6	Of Date 1, And Date D. Nucleotide Analogs From DNA By P53 Protein", pg. 17, Column 1, AP002199400, abstract	
7	K. Grove et al, "Anticancer Activity Of Beta-L-Dioxolane-Cytidine", Cancer Research., Vol. 55, July 15, 1995, pp. 3008-11, XP002199458, American Association For Cancer Research, Baltimore, MD., US	
8	S.A. Rabbani et al, "Effect of Nucleoside Analogue BCH-4556 On Prostate Cancer Growth And Metastases", Cancer Research, Vol. 58, August 1, 1998, pp. 3461-5, XP002199459, American Association For Cancer Research, Baltimore, MD, US	
	No. <sup>1</sup> 4 5 6	Cite No.¹  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  K.L. Grove et al, "Beta-L-(-)-Dioxolane Cytidine As A Potent Compound For The Treatment Of Cancer", Nucleosides & Nucleotides, Vol. 16, No. 7-9, 1997, pp. 1229-33, XP000971189  S.A. Kadhim et al, "Potent Antitumor Activity Of A Novel Nucleoside Analogue", Cancer Research, Vol. 57, November 1, 1997, pp. 4803-4810, XP000971188  Chemical Abstracts, Vol. 133, No. 5, 2000, Columbus, Ohio, US; abstract no. 53116p, Kukhanova, M.: "Excision Of Beta-L-And Beta-D-Nucleotide Analogs From DNA By P53 Protein", pg. 17; column 1; XP002199460, abstract & Nucleosides, Nucleotides Nucleic Acids, Vol. 19, No. 1-2, 2000, pp. 435-446, USA  K. Grove et al, "Anticancer Activity Of Beta-L-Dioxolane-Cytidine", Cancer Research, Vol. 55, July 15, 1995, pp. 3008-11, XP002199458, American Association For Cancer Research, Baltimore, MD., US  S.A. Rabbani et al, "Effect of Nucleoside Analogue BCH-4556 On Prostate Cancer Growth And Metastases", Cancer Research, Vol. 58, August 1, 1998, pp. 3461-5, XP002199459, American Association For Cancer Research, Baltimore, MD, US

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.